EMA Application withdrawn: Kinharto (omecamtiv mecarbil dihydrochloride hydrate) — Cytokinetics (Ireland) Limited

View source ↗

Summary

EMA has withdrawn its application for Kinharto (omecamtiv mecarbil dihydrochloride hydrate) for heart failure with systolic dysfunction.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Reduced Ejection Fraction

Drugs mentioned

• Kinharto (omecamtiv mecarbil dihydrochloride hydrate)

Snippet

Status: Application withdrawn. Therapeutic area: Heart Failure, Systolic. MAH: Cytokinetics (Ireland) Limited